
|Videos|April 7, 2021
Future Therapies in Lipidology
Author(s)Patrick Campbell
In this portion of the panel discussion, panelists examine newer therapies for the treatment of lipid disorders. Included in this section are brief discussions around icosapent ethyl, inclisiran, and bempedoic acid. *This conversation occurred in February 2021 and regulatory approvals/decisions may have changed since filming.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
4
Semaglutide 7.2 mg Shows Greater BMI, Cardiometabolic Gains in T2D
5


























































